12:00 AM
Sep 28, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Alimta pemetrexed regulatory update

The U.K.'s NICE issued guidance recommending the use of Alimta pemetrexed from Eli Lilly for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with cisplatin...

Read the full 132 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >